Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. (Q35906236)

11 August 2017

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. (English)

1 reference

11 August 2017

Matthew T Bennett

1

1 reference

11 August 2017

Kevin W Johns

series ordinal

2

1 reference

11 August 2017

Gregory P Bondy

series ordinal

3

1 reference

11 August 2017

language of work or name

1 reference

13 June 2007

1 reference

Lipids in Health and Disease

11 August 2017

1 reference

11 August 2017

6

1 reference

11 August 2017

15

1 reference

https://scigraph.springernature.com/pub.10.1186/1476-511x-6-15

11 August 2017

0 references

cites work

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

14 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17565701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17565701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1476-511X-6-15

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

1 reference